Efficacy  ||| S:0 E:9 ||| NNP
and  ||| S:9 E:13 ||| CC
tolerability  ||| S:13 E:26 ||| NN
of  ||| S:26 E:29 ||| IN
a  ||| S:29 E:31 ||| DT
cream  ||| S:31 E:37 ||| NN
containing  ||| S:37 E:48 ||| VBG
AR-GG27®  ||| S:48 E:57 ||| NNP
( ||| S:57 E:58 ||| -LRB-
sorbityl  ||| S:58 E:67 ||| FW
furfural  ||| S:67 E:76 ||| FW
palmitate ||| S:76 E:85 ||| FW
)  ||| S:85 E:87 ||| -RRB-
in  ||| S:87 E:90 ||| IN
the  ||| S:90 E:94 ||| DT
treatment  ||| S:94 E:104 ||| NN
of  ||| S:104 E:107 ||| IN
mild ||| S:107 E:111 ||| JJ
/ ||| S:111 E:112 ||| CD
moderate  ||| S:112 E:121 ||| JJ
childhood  ||| S:121 E:131 ||| NN
atopic  ||| S:131 E:138 ||| NNS
dermatitis  ||| S:138 E:149 ||| VBP
associated  ||| S:149 E:160 ||| VBN
with  ||| S:160 E:165 ||| IN
pityriasis  ||| S:165 E:176 ||| JJ
alba ||| S:176 E:180 ||| NN
.  ||| S:180 E:182 ||| .
A  ||| S:182 E:184 ||| DT
double-blind ||| S:184 E:196 ||| JJ
,  ||| S:196 E:198 ||| ,
placebo-controlled  ||| S:198 E:217 ||| JJ
clinical  ||| S:217 E:226 ||| JJ
trial  ||| S:226 E:232 ||| NN
Pityriasis  ||| S:232 E:243 ||| FW
alba  ||| S:243 E:248 ||| FW
( ||| S:248 E:249 ||| -LRB-
PA ||| S:249 E:251 ||| NNP
)  ||| S:251 E:253 ||| -RRB-
is  ||| S:253 E:256 ||| VBZ
a  ||| S:256 E:258 ||| DT
skin  ||| S:258 E:263 ||| NN
disorder  ||| S:263 E:272 ||| NN
characterized  ||| S:272 E:286 ||| VBN
by  ||| S:286 E:289 ||| IN
finely  ||| S:289 E:296 ||| JJ
scaly ||| S:296 E:301 ||| NN
,  ||| S:301 E:303 ||| ,
hypopigmented  ||| S:303 E:317 ||| JJ
patches ||| S:317 E:324 ||| NN
,  ||| S:324 E:326 ||| ,
typical  ||| S:326 E:334 ||| JJ
of  ||| S:334 E:337 ||| IN
childhood ||| S:337 E:346 ||| NN
,  ||| S:346 E:348 ||| ,
that  ||| S:348 E:353 ||| WDT
also  ||| S:353 E:358 ||| RB
represents  ||| S:358 E:369 ||| VBZ
an  ||| S:369 E:372 ||| DT
atopic  ||| S:372 E:379 ||| JJ
dermatitis  ||| S:379 E:390 ||| NNS
( ||| S:390 E:391 ||| -LRB-
AD ||| S:391 E:393 ||| NNP
)  ||| S:393 E:395 ||| -RRB-
minor  ||| S:395 E:401 ||| JJ
sign  ||| S:401 E:406 ||| NN
according  ||| S:406 E:416 ||| VBG
to  ||| S:416 E:419 ||| TO
Hanifin  ||| S:419 E:427 ||| NNP
and  ||| S:427 E:431 ||| CC
Rajka  ||| S:431 E:437 ||| NNP
criteria ||| S:437 E:445 ||| NNS
.  ||| S:445 E:447 ||| .
It  ||| S:447 E:450 ||| PRP
may  ||| S:450 E:454 ||| MD
be  ||| S:454 E:457 ||| VB
isolated  ||| S:457 E:466 ||| VBN
or  ||| S:466 E:469 ||| CC
associated  ||| S:469 E:480 ||| VBN
with  ||| S:480 E:485 ||| IN
AD  ||| S:485 E:488 ||| NNP
representing ||| S:488 E:500 ||| VBG
,  ||| S:500 E:502 ||| ,
sometimes  ||| S:502 E:512 ||| RB
an  ||| S:512 E:515 ||| DT
atypical  ||| S:515 E:524 ||| JJ
manifestation  ||| S:524 E:538 ||| NN
of  ||| S:538 E:541 ||| IN
AD  ||| S:541 E:544 ||| NNP
during  ||| S:544 E:551 ||| IN
the  ||| S:551 E:555 ||| DT
long-term  ||| S:555 E:565 ||| JJ
follow-up  ||| S:565 E:575 ||| NN
of  ||| S:575 E:578 ||| IN
the  ||| S:578 E:582 ||| DT
disease ||| S:582 E:589 ||| NN
.  ||| S:589 E:591 ||| .
Aim  ||| S:591 E:595 ||| NN
of  ||| S:595 E:598 ||| IN
the  ||| S:598 E:602 ||| DT
study  ||| S:602 E:608 ||| NN
was  ||| S:608 E:612 ||| VBD
to  ||| S:612 E:615 ||| TO
evaluate  ||| S:615 E:624 ||| VB
of  ||| S:624 E:627 ||| IN
the  ||| S:627 E:631 ||| DT
efficacy  ||| S:631 E:640 ||| NN
and  ||| S:640 E:644 ||| CC
tolerability  ||| S:644 E:657 ||| NN
of  ||| S:657 E:660 ||| IN
AR-GG27®  ||| S:660 E:669 ||| NNP
( ||| S:669 E:670 ||| -LRB-
sorbityl  ||| S:670 E:679 ||| FW
furfural  ||| S:679 E:688 ||| FW
palmitate ||| S:688 E:697 ||| FW
)  ||| S:697 E:699 ||| -RRB-
cream  ||| S:699 E:705 ||| NN
in  ||| S:705 E:708 ||| IN
the  ||| S:708 E:712 ||| DT
treatment  ||| S:712 E:722 ||| NN
of  ||| S:722 E:725 ||| IN
childhood  ||| S:725 E:735 ||| JJ
mild  ||| S:735 E:740 ||| JJ
or  ||| S:740 E:743 ||| CC
moderate  ||| S:743 E:752 ||| JJ
AD  ||| S:752 E:755 ||| NNS
associated  ||| S:755 E:766 ||| VBN
with  ||| S:766 E:771 ||| IN
PA ||| S:771 E:773 ||| NNP
.  ||| S:773 E:775 ||| .
The  ||| S:775 E:779 ||| DT
trial  ||| S:779 E:785 ||| NN
is  ||| S:785 E:788 ||| VBZ
a  ||| S:788 E:790 ||| DT
single  ||| S:790 E:797 ||| JJ
center ||| S:797 E:803 ||| NN
,  ||| S:803 E:805 ||| ,
double-blind ||| S:805 E:817 ||| NNP
,  ||| S:817 E:819 ||| ,
randomized ||| S:819 E:829 ||| NN
,  ||| S:829 E:831 ||| ,
placebo-controlled  ||| S:831 E:850 ||| JJ
study ||| S:850 E:855 ||| NN
.  ||| S:855 E:857 ||| .
The  ||| S:857 E:861 ||| DT
study  ||| S:861 E:867 ||| NN
included  ||| S:867 E:876 ||| VBD
patients  ||| S:876 E:885 ||| NNS
of  ||| S:885 E:888 ||| IN
both  ||| S:888 E:893 ||| DT
sexes ||| S:893 E:898 ||| NN
,  ||| S:898 E:900 ||| ,
aged  ||| S:900 E:905 ||| VBN
between  ||| S:905 E:913 ||| IN
two  ||| S:913 E:917 ||| CD
months  ||| S:917 E:924 ||| NNS
and  ||| S:924 E:928 ||| CC
15  ||| S:928 E:931 ||| CD
years ||| S:931 E:936 ||| NNS
,  ||| S:936 E:938 ||| ,
suffering  ||| S:938 E:948 ||| VBG
from  ||| S:948 E:953 ||| IN
mild  ||| S:953 E:958 ||| JJ
and  ||| S:958 E:962 ||| CC
moderate  ||| S:962 E:971 ||| JJ
AD  ||| S:971 E:974 ||| NNP
always  ||| S:974 E:981 ||| RB
associated  ||| S:981 E:992 ||| VBN
with  ||| S:992 E:997 ||| IN
PA ||| S:997 E:999 ||| NNP
.  ||| S:999 E:1001 ||| .
Xerosis  ||| S:1001 E:1009 ||| NNP
was  ||| S:1009 E:1013 ||| VBD
present  ||| S:1013 E:1021 ||| JJ
in  ||| S:1021 E:1024 ||| IN
all  ||| S:1024 E:1028 ||| DT
patients ||| S:1028 E:1036 ||| NNS
.  ||| S:1036 E:1038 ||| .
The  ||| S:1038 E:1042 ||| DT
treatment  ||| S:1042 E:1052 ||| NN
with  ||| S:1052 E:1057 ||| IN
topical  ||| S:1057 E:1065 ||| JJ
steroids  ||| S:1065 E:1074 ||| NNS
or  ||| S:1074 E:1077 ||| CC
topical  ||| S:1077 E:1085 ||| FW
calcineurin  ||| S:1085 E:1097 ||| FW
inhibitors  ||| S:1097 E:1108 ||| FW
( ||| S:1108 E:1109 ||| -LRB-
TIMs ||| S:1109 E:1113 ||| NNP
)  ||| S:1113 E:1115 ||| -RRB-
had  ||| S:1115 E:1119 ||| VBD
to  ||| S:1119 E:1122 ||| TO
be  ||| S:1122 E:1125 ||| VB
suspended  ||| S:1125 E:1135 ||| VBN
for  ||| S:1135 E:1139 ||| IN
at  ||| S:1139 E:1142 ||| IN
least  ||| S:1142 E:1148 ||| JJS
15  ||| S:1148 E:1151 ||| CD
days ||| S:1151 E:1155 ||| NNS
.  ||| S:1155 E:1157 ||| .
Any  ||| S:1157 E:1161 ||| DT
systemic  ||| S:1161 E:1170 ||| JJ
therapy  ||| S:1170 E:1178 ||| NN
and  ||| S:1178 E:1182 ||| CC
phototherapy  ||| S:1182 E:1195 ||| NNS
or  ||| S:1195 E:1198 ||| CC
sun  ||| S:1198 E:1202 ||| NN
exposure  ||| S:1202 E:1211 ||| NN
were  ||| S:1211 E:1216 ||| VBD
withdrawn  ||| S:1216 E:1226 ||| VBN
at  ||| S:1226 E:1229 ||| IN
least  ||| S:1229 E:1235 ||| JJS
30  ||| S:1235 E:1238 ||| CD
days  ||| S:1238 E:1243 ||| NNS
before ||| S:1243 E:1249 ||| RB
.  ||| S:1249 E:1251 ||| .
Emollients  ||| S:1251 E:1262 ||| NNP
were  ||| S:1262 E:1267 ||| VBD
stopped  ||| S:1267 E:1275 ||| VBN
at  ||| S:1275 E:1278 ||| IN
least  ||| S:1278 E:1284 ||| JJS
seven  ||| S:1284 E:1290 ||| CD
days  ||| S:1290 E:1295 ||| NNS
before ||| S:1295 E:1301 ||| RB
.  ||| S:1301 E:1303 ||| .
During  ||| S:1303 E:1310 ||| IN
the  ||| S:1310 E:1314 ||| DT
trial ||| S:1314 E:1319 ||| NN
,  ||| S:1319 E:1321 ||| ,
no  ||| S:1321 E:1324 ||| DT
other  ||| S:1324 E:1330 ||| JJ
local  ||| S:1330 E:1336 ||| JJ
or  ||| S:1336 E:1339 ||| CC
systemic  ||| S:1339 E:1348 ||| JJ
treatments  ||| S:1348 E:1359 ||| NNS
were  ||| S:1359 E:1364 ||| VBD
allowed ||| S:1364 E:1371 ||| VBN
,  ||| S:1371 E:1373 ||| ,
as  ||| S:1373 E:1376 ||| RB
well  ||| S:1376 E:1381 ||| RB
as  ||| S:1381 E:1384 ||| IN
sun  ||| S:1384 E:1388 ||| NN
exposure ||| S:1388 E:1396 ||| NN
.  ||| S:1396 E:1398 ||| .
Patients  ||| S:1398 E:1407 ||| NNS
affected  ||| S:1407 E:1416 ||| VBN
by  ||| S:1416 E:1419 ||| IN
AD  ||| S:1419 E:1422 ||| NNP
with  ||| S:1422 E:1427 ||| IN
viral ||| S:1427 E:1432 ||| JJ
,  ||| S:1432 E:1434 ||| ,
bacterial  ||| S:1434 E:1444 ||| JJ
or  ||| S:1444 E:1447 ||| CC
fungal  ||| S:1447 E:1454 ||| JJ
overinfection  ||| S:1454 E:1468 ||| NN
or  ||| S:1468 E:1471 ||| CC
patients  ||| S:1471 E:1480 ||| NNS
with  ||| S:1480 E:1485 ||| IN
diabetes  ||| S:1485 E:1494 ||| JJ
mellitus ||| S:1494 E:1502 ||| NN
,  ||| S:1502 E:1504 ||| ,
severe  ||| S:1504 E:1511 ||| JJ
systemic  ||| S:1511 E:1520 ||| JJ
diseases  ||| S:1520 E:1529 ||| NNS
or  ||| S:1529 E:1532 ||| CC
intolerance  ||| S:1532 E:1544 ||| JJ
to  ||| S:1544 E:1547 ||| TO
one  ||| S:1547 E:1551 ||| CD
or  ||| S:1551 E:1554 ||| CC
more  ||| S:1554 E:1559 ||| JJR
components  ||| S:1559 E:1570 ||| NNS
of  ||| S:1570 E:1573 ||| IN
the  ||| S:1573 E:1577 ||| DT
product  ||| S:1577 E:1585 ||| NN
were  ||| S:1585 E:1590 ||| VBD
excluded ||| S:1590 E:1598 ||| VBN
.  ||| S:1598 E:1600 ||| .
The  ||| S:1600 E:1604 ||| DT
primary  ||| S:1604 E:1612 ||| JJ
endpoint  ||| S:1612 E:1621 ||| NN
was  ||| S:1621 E:1625 ||| VBD
the  ||| S:1625 E:1629 ||| DT
evaluation  ||| S:1629 E:1640 ||| NN
of  ||| S:1640 E:1643 ||| IN
the  ||| S:1643 E:1647 ||| DT
average  ||| S:1647 E:1655 ||| JJ
change  ||| S:1655 E:1662 ||| NN
in  ||| S:1662 E:1665 ||| IN
the  ||| S:1665 E:1669 ||| DT
Investigator  ||| S:1669 E:1682 ||| NNP
Global  ||| S:1682 E:1689 ||| NNP
Assessment  ||| S:1689 E:1700 ||| NNP
( ||| S:1700 E:1701 ||| -LRB-
IGA ||| S:1701 E:1704 ||| NNP
)  ||| S:1704 E:1706 ||| -RRB-
after  ||| S:1706 E:1712 ||| IN
15  ||| S:1712 E:1715 ||| CD
and  ||| S:1715 E:1719 ||| CC
30  ||| S:1719 E:1722 ||| CD
days  ||| S:1722 E:1727 ||| NNS
of  ||| S:1727 E:1730 ||| IN
treatment ||| S:1730 E:1739 ||| NN
.  ||| S:1739 E:1741 ||| .
The  ||| S:1741 E:1745 ||| DT
second  ||| S:1745 E:1752 ||| JJ
endpoint  ||| S:1752 E:1761 ||| NN
was  ||| S:1761 E:1765 ||| VBD
the  ||| S:1765 E:1769 ||| DT
evaluation  ||| S:1769 E:1780 ||| NN
of  ||| S:1780 E:1783 ||| IN
severity  ||| S:1783 E:1792 ||| NN
of  ||| S:1792 E:1795 ||| IN
three  ||| S:1795 E:1801 ||| CD
different  ||| S:1801 E:1811 ||| JJ
clinical  ||| S:1811 E:1820 ||| JJ
signs ||| S:1820 E:1825 ||| NNS
:  ||| S:1825 E:1827 ||| :
erythema ||| S:1827 E:1835 ||| CD
,  ||| S:1835 E:1837 ||| ,
excoriation  ||| S:1837 E:1849 ||| JJ
desquamation ||| S:1849 E:1861 ||| NN
,  ||| S:1861 E:1863 ||| ,
using  ||| S:1863 E:1869 ||| VBG
a  ||| S:1869 E:1871 ||| DT
subjective  ||| S:1871 E:1882 ||| JJ
five-point  ||| S:1882 E:1893 ||| JJ
scale ||| S:1893 E:1898 ||| NN
.  ||| S:1898 E:1900 ||| .
Changes  ||| S:1900 E:1908 ||| NNS
in  ||| S:1908 E:1911 ||| IN
pruritus  ||| S:1911 E:1920 ||| JJ
severity  ||| S:1920 E:1929 ||| NN
was  ||| S:1929 E:1933 ||| VBD
also  ||| S:1933 E:1938 ||| RB
considered  ||| S:1938 E:1949 ||| VBN
during  ||| S:1949 E:1956 ||| IN
the  ||| S:1956 E:1960 ||| DT
entire  ||| S:1960 E:1967 ||| JJ
period  ||| S:1967 E:1974 ||| NN
of  ||| S:1974 E:1977 ||| IN
treatment ||| S:1977 E:1986 ||| NN
,  ||| S:1986 E:1988 ||| ,
through  ||| S:1988 E:1996 ||| IN
the  ||| S:1996 E:2000 ||| DT
use  ||| S:2000 E:2004 ||| NN
of  ||| S:2004 E:2007 ||| IN
a  ||| S:2007 E:2009 ||| DT
Visual  ||| S:2009 E:2016 ||| NNP
Analogue  ||| S:2016 E:2025 ||| NNP
Scale  ||| S:2025 E:2031 ||| NNP
( ||| S:2031 E:2032 ||| -LRB-
VAS ||| S:2032 E:2035 ||| NNP
) ||| S:2035 E:2036 ||| -RRB-
.  ||| S:2036 E:2038 ||| .
A  ||| S:2038 E:2040 ||| DT
P  ||| S:2040 E:2041 ||| NN
< ||| S:2041 E:2042 ||| SYM
0.05 ||| S:2042 E:2046 ||| CD
,  ||| S:2046 E:2048 ||| ,
two  ||| S:2048 E:2052 ||| CD
tailed  ||| S:2052 E:2059 ||| NNS
was  ||| S:2059 E:2063 ||| VBD
considered  ||| S:2063 E:2074 ||| VBN
as  ||| S:2074 E:2077 ||| IN
statistically  ||| S:2077 E:2091 ||| JJ
significant ||| S:2091 E:2102 ||| JJ
.  ||| S:2102 E:2104 ||| .
After  ||| S:2104 E:2110 ||| IN
15  ||| S:2110 E:2113 ||| CD
and  ||| S:2113 E:2117 ||| CC
30  ||| S:2117 E:2120 ||| CD
days  ||| S:2120 E:2125 ||| NNS
there  ||| S:2125 E:2131 ||| EX
was  ||| S:2131 E:2135 ||| VBD
a  ||| S:2135 E:2137 ||| DT
statistically  ||| S:2137 E:2151 ||| JJ
significant  ||| S:2151 E:2163 ||| JJ
difference  ||| S:2163 E:2174 ||| NN
in  ||| S:2174 E:2177 ||| IN
the  ||| S:2177 E:2181 ||| DT
group  ||| S:2181 E:2187 ||| NN
treated  ||| S:2187 E:2195 ||| VBN
with  ||| S:2195 E:2200 ||| IN
AR-GG27® ||| S:2200 E:2208 ||| NNP
,  ||| S:2208 E:2210 ||| ,
compared  ||| S:2210 E:2219 ||| VBN
to  ||| S:2219 E:2222 ||| TO
the  ||| S:2222 E:2226 ||| DT
placebo  ||| S:2226 E:2234 ||| NN
( ||| S:2234 E:2235 ||| -LRB-
respectively ||| S:2235 E:2247 ||| RB
,  ||| S:2247 E:2249 ||| ,
P=0.0007  ||| S:2249 E:2258 ||| NNP
and  ||| S:2258 E:2262 ||| CC
P=0.005 ||| S:2262 E:2269 ||| CD
) ||| S:2269 E:2270 ||| -RRB-
.  ||| S:2270 E:2272 ||| .
After  ||| S:2272 E:2278 ||| IN
15  ||| S:2278 E:2281 ||| CD
days  ||| S:2281 E:2286 ||| NNS
of  ||| S:2286 E:2289 ||| IN
treatment ||| S:2289 E:2298 ||| NN
,  ||| S:2298 E:2300 ||| ,
itching  ||| S:2300 E:2308 ||| NN
was  ||| S:2308 E:2312 ||| VBD
clearly  ||| S:2312 E:2320 ||| RB
reduced  ||| S:2320 E:2328 ||| VBN
in  ||| S:2328 E:2331 ||| IN
AR-GG27®  ||| S:2331 E:2340 ||| CD
treated  ||| S:2340 E:2348 ||| JJ
group  ||| S:2348 E:2354 ||| NN
compared  ||| S:2354 E:2363 ||| VBN
with  ||| S:2363 E:2368 ||| IN
the  ||| S:2368 E:2372 ||| DT
placebo ||| S:2372 E:2379 ||| NN
,  ||| S:2379 E:2381 ||| ,
both  ||| S:2381 E:2386 ||| DT
in  ||| S:2386 E:2389 ||| IN
the  ||| S:2389 E:2393 ||| DT
study  ||| S:2393 E:2399 ||| NN
population  ||| S:2399 E:2410 ||| NN
( ||| S:2410 E:2411 ||| -LRB-
P=0.01 ||| S:2411 E:2417 ||| NNP
)  ||| S:2417 E:2419 ||| -RRB-
and  ||| S:2419 E:2423 ||| CC
in  ||| S:2423 E:2426 ||| IN
patients  ||| S:2426 E:2435 ||| NNS
where  ||| S:2435 E:2441 ||| WRB
the  ||| S:2441 E:2445 ||| DT
symptom  ||| S:2445 E:2453 ||| NN
was  ||| S:2453 E:2457 ||| VBD
present  ||| S:2457 E:2465 ||| JJ
from  ||| S:2465 E:2470 ||| IN
the  ||| S:2470 E:2474 ||| DT
beginning  ||| S:2474 E:2484 ||| NN
( ||| S:2484 E:2485 ||| -LRB-
P=0.05 ||| S:2485 E:2491 ||| NNP
) ||| S:2491 E:2492 ||| -RRB-
.  ||| S:2492 E:2494 ||| .
AR-GG27®  ||| S:2494 E:2503 ||| NNP
showed  ||| S:2503 E:2510 ||| VBD
a  ||| S:2510 E:2512 ||| DT
beneficial  ||| S:2512 E:2523 ||| JJ
action  ||| S:2523 E:2530 ||| NN
associated  ||| S:2530 E:2541 ||| VBN
with  ||| S:2541 E:2546 ||| IN
high  ||| S:2546 E:2551 ||| JJ
compliance  ||| S:2551 E:2562 ||| NN
and  ||| S:2562 E:2566 ||| CC
tolerability  ||| S:2566 E:2579 ||| NN
in  ||| S:2579 E:2582 ||| IN
dermatological  ||| S:2582 E:2597 ||| JJ
skin  ||| S:2597 E:2602 ||| NN
conditions  ||| S:2602 E:2613 ||| NNS
characterized  ||| S:2613 E:2627 ||| VBN
by  ||| S:2627 E:2630 ||| IN
inflammation  ||| S:2630 E:2643 ||| NN
and  ||| S:2643 E:2647 ||| CC
tissue  ||| S:2647 E:2654 ||| NN
oxidative  ||| S:2654 E:2664 ||| NN
stress  ||| S:2664 E:2671 ||| NN
in  ||| S:2671 E:2674 ||| IN
children ||| S:2674 E:2682 ||| NNS
,  ||| S:2682 E:2684 ||| ,
as  ||| S:2684 E:2687 ||| IN
PA  ||| S:2687 E:2690 ||| NNP
with  ||| S:2690 E:2695 ||| IN
mild  ||| S:2695 E:2700 ||| JJ
and  ||| S:2700 E:2704 ||| CC
moderate  ||| S:2704 E:2713 ||| JJ
AD ||| S:2713 E:2715 ||| NNP
.  ||| S:2715 E:2717 ||| .
